Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status
MET-TKIs are effective for NSCLC with the METex14 skipping mutation; however, their efficacy for patients with a poor PS is limited.
Authors
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Yasushi Goto (ORCID: https://orcid.org/0000-0002-7437-5054)
- Yoh Yamaguchi (ORCID: https://orcid.org/0009-0004-6395-2807)
- Yuichiro Ohe
- Ryoko Inaba Higashiyama
- Tatsuya Yoshida
- Yusuke Okuma
- Yuki Shinno
- Ken Masuda
- Hidehito Horinouchi
Institutions
- National Cancer Centre Japan (JP)
- National Cancer Center (US)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18009
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00